CSPC Pharmaceutical Group's EBIT per Share for the
three
months ended in Dec. 2025 was $0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.21.
During the past 12 months, the average EBIT per Share Growth Rate of CSPC Pharmaceutical Group was -18.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -13.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -6.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 10.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CSPC Pharmaceutical Group's EBIT per Share or its related term are showing as below:
CSPCY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -52.9 Med: 19.1 Max: 162.3
Current: -13.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CSPC Pharmaceutical Group was 162.30% per year. The lowest was -52.90% per year. And the median was 19.10% per year.
CSPCY's 3-Year EBIT Growth Rate is ranked worse than 80.47% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs CSPCY: -13.90
CSPC Pharmaceutical Group (OTCPK:CSPCY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CSPC Pharmaceutical Group EBIT per Share Related Terms
CSPC Pharmaceutical Group EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (CSPCY) has a EBIT per Share of $0.21 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CSPC Pharmaceutical Group and its competitors. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #651 out of 809 companies in the Drug Manufacturers industry, placing it in the top 80.5%.
Is CSPC Pharmaceutical Group's EBIT per Share too high?
CSPC Pharmaceutical Group's current EBIT per Share is $0.21. The Drug Manufacturers industry median EBIT per Share is 7.60. CSPC Pharmaceutical Group's value of $0.21 is 97.2% below this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #651 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CSPC Pharmaceutical Group has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #651 out of 809 companies for EBIT per Share. This places CSPC Pharmaceutical Group in the lower half of its industry. The industry median EBIT per Share is 7.60. CSPC Pharmaceutical Group's value of $0.21 is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current EBIT per Share of $0.21 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current EBIT per Share is $0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.16, compared to a current price of $3.84 — trading 21.5% above its estimated fair value. The current EBIT per Share is $0.21 and 97.2% below the Drug Manufacturers industry median of 7.60. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current EBIT per Share is $0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $3.84 is trading 21.5% above its estimated GF Value™ of $3.16.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
EBIT per Share: $0.21
GF Value™: $3.16 vs. price of $3.84 (21.5% above fair value)
Industry Position: 97.2% below the Drug Manufacturers median (#651 of 809)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score
Get the complete analysis for CSPCY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
